Becoming a Treatment-Ready FSHD Community: Key Takeaways from the World FSHD Alliance Skill Share

| Posted on |

How can the global FSHD community prepare for the arrival of the first therapies? This was the central question explored during the latest quarterly skill share meeting of the World FSHD Alliance, featuring Dr. Michelle Mellion, former leader of the FSHD program at Fulcrum Therapeutics and current Medical Advisor to the FSHD Society.

The discussion highlighted an exciting reality: after years of limited therapeutic development, there are now between 20 and 30 companies actively pursuing FSHD treatments, including gene therapies, oligonucleotides, small molecules, and muscle-regeneration approaches.

What Does “Treatment-Ready” Mean?
While scientific progress is accelerating, Dr. Mellion emphasized that successful treatments alone will not guarantee patient access. Communities, healthcare systems, and individual patients must also be prepared.

Several practical steps were highlighted:

  • Obtain genetic confirmation of an FSHD diagnosis.
  • Connect with a neuromuscular specialist early.
  • Ensure the correct diagnostic coding is included in medical records.
  • Build a multidisciplinary care team.
  • Stay informed about emerging therapies and clinical trials.

Her strongest message was simple:
“If there’s one thing that you can do today, if you have not already done it: get tested.”
— Dr. Michelle Mellion, Medical Advisor FSHD Society

Why Patient Organizations Matter
The session also reinforced the critical role of patient organizations in the treatment landscape. Companies planning clinical trials need information about patient populations, potential trial sites, and specialist clinicians. Even small organizations can contribute by maintaining basic patient and healthcare provider information and staying connected to international networks.

Registries were identified as particularly important, helping researchers better understand the disease while strengthening clinical trial readiness.

A Message of Hope
The meeting concluded with a powerful reminder from Jack: there is genuine reason for optimism as multiple therapeutic programs continue to advance through clinical development. At the same time, the community must remain realistic, informed, and united. The goal is not only to achieve effective treatments, but to ensure that patients worldwide can benefit from them.

As Dr. Mellion noted, the science is making remarkable progress. The next challenge is ensuring that the global FSHD community is ready when treatments arrive.

To watch the full session, please contact us below: